Resverlogix Corp T.RVX

RE:AGM nearing

[toinv261]

Hey GV, I am afraid you are right.

It will be the usual rubber stamp session approving the board and other standard requirements for an AGM. No challenging questions will be asked and very little time will be allocated for questions. The attendies will be a friendly crowd and I doubt that any new information will be revealed.

Don will say BETonMACE is proceeding well and "we are pretty excited about that". He won't address enrolment/dosing specifics. Perhaps he will address possible FDA approval but my guess is he'll say "we are still working on that". There may be a hint about an orphan trial but it will be non-committal. 

Cash burn rate will probably be addressed. When asked about status of raising funds for continued operations Don will will reply that "we are in biotech...we are always raising funds". However, my guess is that the Citi line of credit renewal in 2017 will not be addressed (and of course this is a very big concern for many investors). There will not be a hard look at the really key concerns and it will be a sort of "trust me...things are moving along" attitude.

There will not be any concrete information about a new regional deal.

Any analysts that attend willl be friendly and will not push Don.

Time allocated for questions will be extremely limited as usual.

SO TO BE CLEAR HERE, THESE ARE JUST MY VERY HUMBLE OPINIONS BASED ON PAYING ATTENTION OVER THE PAST 5 YEARS. I HAVE NO FACTS AND I CANNOT PREDICT THE FUTURE BUT HISTORY TELLS ME NOTHING WILL CHANGE.

However, could things change...I sure don't know, but they did hire a VP of IR who doesn't seem to have achieved anything yet BUT it does take time to get up to speed in a new business. I'll give him the benefit of the doubt.

So IMHO there is absolutely nothing at all to get excited about. The AGM is just a legal requirement and it will come an go without notice.

So now if we look on the hypothetical side then what would make the AGM of interest and value?

1. Announcement of a new regional partner or concrete status of progress (won't happen).
2. If a regional deal is in place then appointment to the board and what does this imply strategically in terms of both business and science?
3. If there is a new regional partner then what is the funding, structure and the implications for the Citi LOC renewal.
4. Status of relationships with NGN and Eastern.
5. Hepalink's involvement in the BETonMACE trial.
6. Concrete status of the BETonMACE trial (won't happen).
7. Addition of new scientists to the team.
8. Etc

Anyway, I'm still long and I believe in the science. 

There are a few things over the next 18 months that might help pop the share price IMHO!

1. Rumors that will get out as a new regional deal develops (witness Hepalink).
2. Passing the futility analysis.
3. Concrete information about the Citi LOC.
4. Possibly an orphan trial but????
5. Rumors of a possible CVR type deal with a BP.

GLTA
Cheers
Toinv